Hepion Pharmaceuticals, Inc. (HEPA) company profile
Close on Oct 19, 2026Market cap $7.26MP/E –Yield –
About Hepion Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Hepion Pharmaceuticals, Inc. operates as a medical diagnostic company focused on diagnostic solutions. The company previously concentrated on developing drug therapies for chronic liver conditions, specifically its cyclophilin inhibitor rencofilstat, before divesting all related patent assets, clinical data, and drug materials. Currently, Hepion in-licenses diagnostic tests covering conditions such as celiac disease, respiratory multiplex infections, Helicobacter pylori, and hepatocellular carcinoma, alongside licensed liver disease diagnostic assets. It targets healthcare markets seeking clinical diagnostic tools.
The company maintains its principal executive offices in Morristown, New Jersey. Its licensed tests for celiac disease, respiratory multiplex, and Helicobacter pylori hold CE marks, making them eligible for commercial sale within the European Union and other participating territories that recognize CE certification, while excluding the United States. Hepion does not possess internal commercialization, sales, marketing, or manufacturing facilities, relying instead on external arrangements and collaborations to advance and distribute its diagnostic product portfolio across authorized regional markets.
Summary of the business section of Hepion Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Hepion Pharmaceuticals, Inc.
- Founded
- 2013
- Headquarters
- Red Bank, NJ
- Address
- 34 Shrewsbury Ave., Suite 1d 07701
- Phone
- (732) 902-4000
- Website
- hepion.com
- Employees
- 2, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Grassi & Co., CPAs, P.C, Jericho, New York
Stock & identifiers
- Ticker
- HEPA
- Other tickers
- CTRVP
- Exchange
- OTC
- IPO date
- Feb 10, 2014
- Shares outstanding
- 90M, Aug 10, 2026
- Public float
- $900.00K, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-50 reverse, Mar 18, 2025; 1-for-20 reverse, May 11, 2023; 1-for-70 reverse, Jun 3, 2019; 1-for-8 reverse, May 29, 2018
- SEC CIK
- 1583771
- FIGI
- BBG005Y0S0J9
- Share class FIGI
- BBG005Y0S0K7
- EIN
- 46-2783806
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sireesh Appajosyula | Chief Executive Officer, Director | 3,250,000 |
| Vincent S. LoPriore | Executive Chairman, Director | 30,500,000 |
| Gary S. Stetz | Chief Financial Officer, Director | 4,500,000 |
| Chase LoPriore | VP, Corp. Dev., Director | 1,250,000 |
| James Gordon Liddy | Director | – |
| Danina Fisher | Director | 200,000 |
| Gary S. Stetz II | Director | 500,000 |
| Michael J. Purcell | Director | 3,250,000 |
| Collective Corp. Gravitas | Director | 25,000,000 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Total | vs. prior year |
|---|---|---|---|
| John Brancaccio Former Interim Chief Executive Officer and Chief Financial Officer | $232.50K | $232.50K | -54% |
| Kaouthar Lbiati Former Chief Executive Officer | $198.02K | $198.02K | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had two employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?